[
  {
    "ts": null,
    "headline": "Those who invested in Abbott Laboratories (NYSE:ABT) three years ago are up 39%",
    "summary": "Low-cost index funds make it easy to achieve average market returns. But in any diversified portfolio of stocks, you'll...",
    "url": "https://finnhub.io/api/news?id=9a5e62fcc1fa86233882ccf5df269bd60c46ddbb2908337677c10c5b92b7055b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760187608,
      "headline": "Those who invested in Abbott Laboratories (NYSE:ABT) three years ago are up 39%",
      "id": 137063607,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Low-cost index funds make it easy to achieve average market returns. But in any diversified portfolio of stocks, you'll...",
      "url": "https://finnhub.io/api/news?id=9a5e62fcc1fa86233882ccf5df269bd60c46ddbb2908337677c10c5b92b7055b"
    }
  },
  {
    "ts": null,
    "headline": "JPMorgan, Goldman Sachs Among Big Banks Set To Report Earnings Next Week",
    "summary": "Next week will witness a slew of earnings from banking giants. Investors will keep a close eye on economic reports that will be released next week. See more.",
    "url": "https://finnhub.io/api/news?id=23254b97506ed5e3c990993bec734ce6f84d8f030caeb8c4ed6bc7751c94b060",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760180400,
      "headline": "JPMorgan, Goldman Sachs Among Big Banks Set To Report Earnings Next Week",
      "id": 137051504,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "ABT",
      "source": "SeekingAlpha",
      "summary": "Next week will witness a slew of earnings from banking giants. Investors will keep a close eye on economic reports that will be released next week. See more.",
      "url": "https://finnhub.io/api/news?id=23254b97506ed5e3c990993bec734ce6f84d8f030caeb8c4ed6bc7751c94b060"
    }
  },
  {
    "ts": null,
    "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of October 12",
    "summary": "Read here for the latest weekly summary of dividend changes, ex-dividend dates, and pay dates for Dividend Champions, Contenders, and Challengers.",
    "url": "https://finnhub.io/api/news?id=cd67ada37dbc5c921fbb362f86d137eec66e12b9eb7af59b055f212b4879ab01",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760148201,
      "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of October 12",
      "id": 137047507,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
      "related": "ABT",
      "source": "SeekingAlpha",
      "summary": "Read here for the latest weekly summary of dividend changes, ex-dividend dates, and pay dates for Dividend Champions, Contenders, and Challengers.",
      "url": "https://finnhub.io/api/news?id=cd67ada37dbc5c921fbb362f86d137eec66e12b9eb7af59b055f212b4879ab01"
    }
  },
  {
    "ts": null,
    "headline": "Biotech Stocks Have Struggled Since 2021. Why They’re Coming Back.",
    "summary": "Too many questionable start-ups went public during the pandemic, when the sector was hot. Now, after over four years of pain, the weak have failed, rates are falling, and M&A looks to be on the upswing.",
    "url": "https://finnhub.io/api/news?id=0c37777d4a658fa4dcbd69eea2e7456da295d35bc8206da0a75f130d74302ed7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760141880,
      "headline": "Biotech Stocks Have Struggled Since 2021. Why They’re Coming Back.",
      "id": 137049056,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Too many questionable start-ups went public during the pandemic, when the sector was hot. Now, after over four years of pain, the weak have failed, rates are falling, and M&A looks to be on the upswing.",
      "url": "https://finnhub.io/api/news?id=0c37777d4a658fa4dcbd69eea2e7456da295d35bc8206da0a75f130d74302ed7"
    }
  },
  {
    "ts": null,
    "headline": "Benchmark Initiates Coverage of Abbott Laboratories (ABT) with Buy Recommendation",
    "summary": "Benchmark Initiates Coverage of Abbott Laboratories (ABT) with Buy Recommendation",
    "url": "https://finnhub.io/api/news?id=9045ed36d364953c685557dabe29334d3edc4cdeecb1d6a93fca6ffdcee8eec4",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760141299,
      "headline": "Benchmark Initiates Coverage of Abbott Laboratories (ABT) with Buy Recommendation",
      "id": 137046111,
      "image": "",
      "related": "ABT",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=9045ed36d364953c685557dabe29334d3edc4cdeecb1d6a93fca6ffdcee8eec4"
    }
  }
]